HORIZONS

UNIVERSITY OF Southampton

Understanding the impact of cancer diagnosis and treatment on everyday life

36 MONTH OVARIAN CANCER CRF

(please also use for primary peritoneal and fallopian tube cancers)

FOR STAFF USE ONLY

CRF Completion Instructions

- **Please complete as much of the CRF as possible**
- **Please refer to your copies of previous CRFs when completing this 36 month CRF: please complete any additional treatment details that were not captured at 24 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)**
- **If you have any queries, please contact the HORIZONS Co-ordinating Centre, email address HORIZONS@soton.ac.uk**
- **Please tick boxes when appropriate**
- **When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet**

Participant's Study ID | | / | | / | | | | |

Participant's date of birth | d | d | | m | m | | y | y | y | y |

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Participant's Study ID ☐☐ / ☐☐ / ☐☐☐☐

Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details) _____	
Other (please give details) _____	
Other (please give details) _____	

Participant's Study ID ☐☐ / ☐☐ / ☐☐☐☐

Is the participant pre or post menopause? (please tick one box)

Pre menopause	
Post menopause	
Unknown	

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	**Specific treatment details**	**Tick if patient has received**	**Date of surgery or start date of other treatment (dd/mm/yyyy)**	**End date of treatment (if finished) (dd/mm/yyyy)**	**If course of treatment was not completed as planned, please give a reason why**
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery) _____		__ / __ / 20___		
Radiotherapy	Radiotherapy		__ / __ / 20___	__ / __ / 20___	
	Number of radiotherapy fractions, please enter on line _____				
	Dose for each radiotherapy fraction please enter on line _____				
Hormone Therapy	please give details below _____		__ / __ / 20___	__ / __ / 20___	

Participant's Study ID ☐☐ / ☐☐ / ☐☐☐☐

Treatment type	Specific treatment details	Tick if patient has received	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Chemotherapy	Drug(s), please tick all that apply				
	Carboplatin		__ / __ / 20___	__ / __ / 20___	
	Weekly Paclitaxel		__ / __ / 20___	__ / __ / 20___	
	Three Weekly Paclitaxel		__ / __ / 20___	__ / __ / 20___	
	Abraxane (Paclitaxel protein bound)		__ / __ / 20___	__ / __ / 20___	
	Liposomal doxorubicin		__ / __ / 20___	__ / __ / 20___	
	Docetaxel		__ / __ / 20___	__ / __ / 20___	
	Gemcitabine		__ / __ / 20___	__ / __ / 20___	
	Topotecan		__ / __ / 20___	__ / __ / 20___	
	Etoposide		__ / __ / 20___	__ / __ / 20___	
	Cyclophosphamide		__ / __ / 20___	__ / __ / 20___	
	Other (please describe below): _____		__ / __ / 20___	__ / __ / 20___	
	Chemotherapy number of cycles, please enter on line _____				
Maintenance Treatment	Please give details of any drugs used as maintenance therapy _____		__ / __ / 20___	__ / __ / 20___	
Additional Treatment	If any additional treatment has been given please describe _____		__ / __ / 20___	__ / __ / 20___	

Participant's Study ID | | / | | / | | | | |

Were any of the treatments detailed given with **palliative intent**?

(please tick one box)

Yes		No		Unknown	

If yes, please indicate which treatments?

_____

Has the participant had a **local** recurrence of their ovarian, primary peritoneal or fallopian tube cancer? (please tick one box)

Yes		No		Unknown	

If the participant has had a **local** recurrence, on what date was the recurrence diagnosed?

d	d	m	m	y	y	y	y

Since the participant's diagnosis of their ovarian, primary peritoneal or fallopian tube cancer, has there been any evidence of distant metastatic disease? (please tick one box)

Yes		No		Unknown	

If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:

d	d	m	m	y	y	y	y

Please provide details of the site(s) of distant metastatic disease:

_____

Is the participant taking part in a clinical trial? (please tick one box)

Yes		No		Unknown	

If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in

Name of clinical trial _____

Participant's Study ID | | / | | / | | | | |

Since the participant's diagnosis of ovarian, primary peritoneal or fallopian tube cancer, have they been diagnosed with another new primary cancer? (please tick one box)

Yes		No		Unknown	

If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below

Type of cancer	
Date of diagnosis	__ / __ / 20___
Treatment received	
Date treatment ended (if finished)	__ / __ / 20___

What type of follow-up care is the participant receiving? (please tick ONE box)

Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this? d d m m y y y y	

Participant's Study ID ☐☐ / ☐☐ / ☐☐☐☐

Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)

Participant has been referred to palliative care services If available, please give reason for referral (e.g. end of life care, symptom management) _____	
Participant has been referred to psychological services If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies) _____	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. pain clinic) If ticked, please provide more details below: _____	
Participant has had an HNA (holistic needs assessment)	
Participant has been referred to fertility services	

If the participant has died please give the date and cause of death:

Participant's date of death d d / m m / y y y y

Cause of participant's death

1) a)	
1) b)	
1) c)	
2)	

Cause of death not known ☐

Please add your name and signature and the date that you completed this CRF

Name _____ Signature _____

Date CRF completed d d / m m / y y y y